周五的标签扩展将有助于葛兰素史克在呼吸道合胞病毒疫苗竞赛中保持领先地位。Arexvy 于 2023 年 5 月成为业内首个获得 FDA 批准的呼吸道合胞病毒疫苗，比其主要竞争对手辉瑞的 Abrysvo 提前一个月。

8月3日， 沃森生物 公告显示，公司与复旦大学、上海蓝鹊生物联合研发的RSV mRNA疫苗，已正式获国家药监局临床试验申请受理。这款基于自主研发mRNA技术平台的疫苗，瞄准的是预防RSV感染引起的下呼吸道相关疾病—— ...

作为儿科医生，曾经面对呼吸道合胞病毒（RSV）感染时，总有一种无力感。但今年略有不同，因为药物预防RSV感染已取得阶段性突破。去年国内开展注射的尼塞韦单抗（乐唯初），可有效减少婴幼儿重症RSV感染的发生。01药物预防目前有三种药物预防方式：1、单克隆 ...

8月3日晚间沃森生物 (300142)公告，公司与复旦大学、上海蓝鹊生物医药有限公司等联合研发的呼吸道合胞病毒mRNA疫苗已向国家药品监督管理局申请临床试验，并于近日获得受理。该疫苗为基于自主研发的“mRNA疫苗技术平台”开发，用于预防呼吸道合胞病毒感染引起的下呼吸道相关疾病。

近年来，呼吸道合胞病毒（RSV）感染成为了全球儿童健康的重要挑战。根据统计，RSV是导致婴幼儿住院和重症肺炎的重要病因之一。随着科学技术的不断进步，疫苗研发逐渐成为预防和控制RSV感染的重要手段。近日，沃森生物与复旦大学等机构联合研发的呼吸道合胞病毒mRNA疫苗，获得了国家药品监督管理局的临床研究申请受理，这一消息无疑为家长们带来了新的希望。

Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world. It had an exceptional launch and generated £1.2 billion in sales in 2023.

AREXVY is indicated for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, as well as individuals 50 through 59 years of age who are ...

GSK (GSK) announces that its Arexvy vaccine shows promise in protecting adults aged 60+ against RSV over three seasons in a Phase 3 trial. Read more here.

财联社10月8日讯（编辑 牛占林）目前呼吸道合胞病毒 (RSV)疫苗被认为是市场上最有想象力的疫苗产品，全球主要疫苗制造商纷纷入局，但最新数据 ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

Since June 2023, Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) has been approved in Europe for adults aged 60 and over for the prevention of RSV-LRTD.

This respiratory syncytial virus (RSV) season is the first time vaccination for this potentially serious infectious disease ...